- FDA Breakthrough Designation for CIN Indication: Plinabulin for Concurrent Administration with Myelosuppressive Chemotherapeutic Regimens in Patients with Non-Myeloid Malignancies for the Prevention of Chemotherapy-Induced Neutropenia (CIN) - - Designation Based on PROTECTIVE-2 Phase 3 Interim Data, Reinforcing Significant Treatment Need in CIN - - Among the First Three Innovative Drugs to Receive Breakthrough Therapy Designations in China - NEW YORK, Sept.
Recent Comments